West Haven, Connecticut 06516

  • Migraine Headache

Purpose:

In seeking to understand the capacity for psilocybin to reduce migraine headache burden, this study will investigate single and repeated dosing of psilocybin up to two doses. In seeking to identify an underlying mechanism in psilocybin's effects, neuroinflammatory markers for migraine headache will be measured.


Study summary:

Migraine headache is a common medical condition and a top cause of disability worldwide. Treatment options for migraine headache are many and varied, though an approximated 10% of migraineurs is refractory to medication and thus, there is a need to develop alternative treatments. There is anecdotal evidence supporting lasting therapeutic effects after limited dosing of psilocybin and related compounds in headache disorders. The cause of this unique effect remains unknown, though the drug class has demonstrable anti-inflammatory activity, a biological process relevant to migraine and other headache disorders. In seeking to understand the capacity for psilocybin to reduce migraine headache burden, this study will investigate single and repeated dosing of psilocybin up to two doses. In seeking to identify an underlying mechanism in psilocybin's effects, neuroinflammatory markers for migraine headache will be measured. The results from this study will serve in the development of larger investigations seeking to understand the effects of psilocybin and related compounds in headache disorders.


Criteria:

Inclusion Criteria: - Diagnosis of migraine headache per ICHD-3 criteria - Typical pattern of migraine attacks with approximately two migraines or more weekly - Attacks are managed by means involving no more than twice weekly triptan use Exclusion Criteria: - Axis I psychotic or manic disorder (e.g., schizophrenia, bipolar I, depression with psychosis) - Axis I psychotic or manic disorder in first degree relative - Unstable medical condition; severe renal, cardiac, or hepatic disease; pacemaker; or serious central nervous system pathology - Pregnant, breastfeeding, lack of adequate birth control - History of intolerance to psilocybin, lysergic acid diethylamide (LSD), or related compounds - Drug abuse within the past 3 months (excluding tobacco) - Urine toxicology positive to drugs of abuse - Alcohol use of >21 drinks per week (males); >14 drinks per week (females; NIAAA guidelines) - Use of alcohol in the week prior to the first test day - Use of vasoconstrictive medications (i.e., sumatriptan, pseudoephedrine, midodrine) within 5 half-lives of test days - Use of serotonergic antiemetics (i.e., ondansetron) in the past 2 weeks - Use of antidepressant medication (i.e., TCA, MAOI, SSRI) in the past 6 weeks - Use of steroids or certain other immunomodulatory agents (i.e., azathioprine) in the past 2 weeks - Use of migraine onabotulinum toxin (i.e., Botox) or monoclonal antibodies against CGRP or its receptor (i.e., erenumab) in the past month or while therapeutic effects are still present


NCT ID:

NCT04218539


Primary Contact:

Mackenzie Creighton, BS
Phone: 203-932-5711 ext. 2526
Email: mackenzie.creighton@yale.edu


Backup Contact:

Email: emmanuelle.schindler@yale.edu
Emmanuelle Schindler, MD PhD
Phone: 203-932-5711 ext. 4335


Location Contact:

West Haven, Connecticut 06516
United States

Mackenzie Creighton, BS
Phone: 203-932-5711
Email: mackenzie.creighton@yale.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: September 24, 2022

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.